Metrics as of 10/17/2026, 08:25 AM (Berlin time), refresh in progress.
Werewolf Therapeutics Stock
Werewolf Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Daniel J. Hicklin
- Employees
- 39
- Market cap
- $48 M
- IPO
- 30/04/2021
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This…
Werewolf Therapeutics stock: price history
1D
-1.7%
1W
+0.0%
1M
+6.6%
6M
+3.6%
YTD
+54.7%
1Y
-41.3%
2Y
-52.4%
5Y
-94.3%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~4% weaker price swings than usual
Ask the agents about Werewolf Therapeutics
Analyst assessment of Werewolf Therapeutics
PRICE TARGET LOW
US$1.00
CONSENSUS
US$6.50
MEDIAN
US$6.50
PRICE TARGET HIGH
US$12.00
0
STRONG BUY
8
BUY
1
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 19/12/2025
Werewolf Therapeutics stock metrics
P/E
-1.33
P/B
2.92
EV/EBITDA
-1.16
RETURN ON EQUITY
22.5%
NET MARGIN
17.5%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
82.2%
FLOAT SHARES
39,927,417
AVG. DAILY VOLUME (30D)
630,361
Insider transactions (SEC)
EVNIN LUKE
EVNIN LUKE
EVNIN LUKE
RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P.
Institutional holders
Comparable stocks
Frequently asked questions about Werewolf Therapeutics stock
What does Werewolf Therapeutics do?
Werewolf Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Daniel J. Hicklin, the company employs around 39 people.
The IPO was on 30/04/2021; the stock trades on NASDAQ under the ticker HOWL.
What do analysts say about Werewolf Therapeutics stock?
9 analysts rate the stock, the consensus is Buy (as of 19/12/2025).
The average price target is US$6.50, ranging from US$1.00 to US$12.00, with a median of US$6.50.
This is an external assessment, not a statement by Market Jury.
When does Werewolf Therapeutics report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly -4% stronger than usual.
Does Werewolf Therapeutics pay a dividend?
No, Werewolf Therapeutics currently does not pay a dividend.
Which stocks are comparable to Werewolf Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Werewolf Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Werewolf Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.